6 research outputs found
Nontoxic Metal–Cyclam Complexes, a New Class of Compounds with Potency against Drug-Resistant <i>Mycobacterium tuberculosis</i>
Tuberculosis
(TB)
accounted for 1.5 million deaths in 2014, and
new classes of anti-TB drugs are required. We report a class of functionalized
1,8-disubstituted cyclam derivatives that display low micromolar activity
against pathogenic mycobacteria. These compounds inhibit intracellular
growth of <i>Mycobacterium tuberculosis</i>, are nontoxic
to human cell lines, and are active against multidrug-resistant <i>M. tuberculosis</i> strains, indicating a distinct mode of action.
These compounds warrant further appraisal as novel agents to control
TB in humans
Serpulanines A to C, N‑Oxidized Tyrosine Derivatives Isolated from the Sri Lankan Fungus <i>Serpula</i> sp.: Structure Elucidation, Synthesis, and Histone Deacetylase Inhibition
Serpulanines A (<b>1</b>),
B (<b>2</b>), and C (<b>3</b>) have been isolated from
extracts of the rare Sri Lankan
macrofungus <i>Serpula</i> sp. The structures of <b>1</b>, <b>2</b>, and <b>3</b> were elucidated by a combination
of spectroscopic and single-crystal X-ray diffraction analyses. Serpulanines
A (<b>1</b>) and B (<b>2</b>) both contain the rare (<i>E</i>)-2-hydroxyimino hydroxamic acid functional group array.
A proposed biogenesis for serpulanine B (<b>2</b>) suggests
that its (<i>E</i>)-2-hydroxyimino hydroxamic acid moiety
arises from a diketopiperazine precursor. Synthetic serpulanine A
(<b>1</b>) inhibited class I/II histone deacetylases in murine
metastatic lung carcinoma cells with an IC<sub>50</sub> of 7 μM
Additional file 4: Figure S2. of Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
Locally Weighted Scatterplot Smoothing curves for FVC% predicted. a. Mild physiological impairment (FVC ≥ 80%). b. Moderate-severe physiological impairment (FVC < 80%). c. Summary of LOWESS curve means. (ZIP 212 kb
Additional file 3: Figure S1. of Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
Exploratory analysis of varying thresholds. (PNG 100 kb
Additional file 2: Table S2. of Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry
Baseline characteristics of patients excluded from analysis. (DOC 35 kb